Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 9/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 8/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18134234 | 0.84 | AKR1C3 (0.46) | AKR1C3AKR1C2PTGS2TGFBR1PDE3B | |
| SCHEMBL10303264 | 0.83 | CNR2 (0.44) | FEN1ALOX5APGRIN2B | |
| SCHEMBL10303392 | 0.81 | FEN1 (0.45) | FEN1ALOX5APGRIN2B | |
| SCHEMBL17359264 | 0.78 | FEN1 (0.40) | FEN1ALOX5APAKR1C3AKR1C2TGFBR1 | |
| SCHEMBL17356648 | 0.77 | GCGR (0.39) | FEN1ALOX5APUSP7 | |
| SCHEMBL10303348 | 0.77 | PIM1 (0.42) | FEN1ALOX5AP | |
| SCHEMBL16852357 | 0.76 | AKR1C3 (0.47) | FEN1ALOX5APAKR1C3AKR1C2PTGS2 | |
| SCHEMBL4402602 | 0.75 | CCR1 (0.54) | FEN1ALOX5APPTGS2 | |
| SCHEMBL19154379 | 0.75 | PTGS2 (0.45) | FEN1ALOX5APPTGS2GRIN2BSLC22A12 | |
| SCHEMBL18069651 | 0.73 | AKR1C3 (0.53) | FEN1ALOX5APAKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9527870-B2 | Liquid crystal compound, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC PETROCHEMICAL CORPORATION (JP) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368272-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | YBX3, OCIAD1, PIEZO1 | FEN1 1419/4885ALOX5AP 1818/4885AKR1C3 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.